^
    Back
    Association details:
    Biomarker:SETD2 overexpression
    Cancer:Diffuse Large B Cell Lymphoma
    Regimen: (Rituxan (rituximab) + cyclophosphamide + doxorubicin hydrochloride + prednisone + vincristine)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASH 2023
    Title:

    Assessment of the Expression of Genes Related to Epigenetic and Chromatin Modifications in Diffuse Large B-Cell Lymphoma Patients Resistant to R-CHOP

    Published date:
    11/02/2023
    Excerpt:
    Patients who had early failure to R-CHOP tended to have higher expression of these genes: SMARCA4 (p=0.010), SETD1B (p=0.018), SETD2 (p=0.024), EP300 (p=0.012), MLL3 (p=0.049), INO80 (p=0.001), CHD8 (p=0.007), NCOR1 (p=0.020), ARID1B (p=0.034), and SETD5 (p=0.007). Compared to the patients who were in remission after R-CHOP therapy, these patients had significantly higher expression of HIST1H1E (p=0.007).
    DOI:
    https://doi.org/10.1182/blood-2023-180349